INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a common and potentially fatal antibody-mediated adverse event (AE), strongly associated with both venous and arterial thrombosis in patients receiving heparin or lowmolecular-weight (LMWH) therapy. [1] [2] [3] [4] [5] Postsurgical patient populations, in particular orthopedic, cardiac, and vascular surgery patients, are at the highest risk for HIT (1-5%). 6 Diagnosis of HIT, a clinicopathologic syndrome, is based on a presenting clinical picture, such as (1) an otherwise unexplained drop in platelet count by 1 30-50% from the baseline count 5 or more days after starting heparin or LMWH (or within 24 hours in patients with recent heparin exposure); (2) venous or arterial thrombosis; (3) skin lesions at heparin or LMWH injection sites; (4) or an acute systemic reaction that occurs after administration of intravenous (IV) and subcutaneous (SC) heparin, in the presence of heparindependent antibodies detected by in vitro assays. 6 Because the initial diagnosis can be difficult, whenever a clinical suspicion of HIT exists, treatment should be initiated while laboratory confirmation is pending. 6, 7 Treatment with unfractionated or LMWH (including heparin products used in IV lines to maintain patency, with dialysis, or with total parenteral nutrition) should be discontinued immediately upon diagnosis or clinical suspicion of HIT. 7 Despite sometimes critically depressed platelet counts, a paradoxically hypercoagulable state is induced by HIT due to increased thrombin generation and pathologic activation of platelets by circulating antibodies to platelet factor-4. 6, 8, 9 Because this hypercoagulable state may persist for days or weeks after initial exposure to heparin, discontinuation of heparin alone is an insufficient management strategy. 6 The use of an alternative, nonheparin anticoagulant, such as a direct thrombin inhibitor (DTI), is necessary after the discontinuation of heparin treatment to offset the hypercoagulability induced by HIT. 1, 6 Without the administration of an alternative anticoagulant agent, the reported risk of thrombosis can be as high as 53%, with an overall risk of fatal thrombosis up to 5%. 1, 6 DTIs effectively lower the risk for thrombotic events in patients with HIT; however, in some clinical studies, their use has been associated with an increased risk of bleeding. 1, 6, 7, 10 Major bleeding is the most important treatment-related AE associated with DTIs, and it is the primary treatment-related AE evaluated in efficacy and tolerability studies on the use of DTIs to prevent thrombosis. 1, 6, 7, [10] [11] [12] At therapeutic doses, major bleeding reportedly occurs in 6-20% of patients after DTI initiation. 6 Because of this risk, DTIs should be used cautiously in patients who have undergone recent cardiac bypass or surgeries related to the brain, spinal cord, or eye. 7, 13 Argatroban is the only DTI currently approved in the United States for both the prophylaxis and treatment of thrombosis in patients with HIT. 13 The efficacy profile of argatroban in patients with HIT is supported by 2 prospective clinical studies. 14, 15 In both studies, a significant reduction occurred in the composite risk of death, amputation, and new thrombosis in patients treated with argatroban compared with historic controls who did not receive a DTI [25.6% (41 of 160 patients) vs 38.8% (57 of 147 patients); P = 0.014 for study 1 and 28.0% (53 of 189 patients) vs 38.8% (54 of 139 patients); P = 0.04 for study 2]. However, in patients with HIT with thrombosis syndrome, the incidence of the primary outcome measure was not significantly different for the argatroban group compared with historic controls in either study. Relative ratios for increased risk of major bleeding events during treatment with argatroban, although not statistically significant, have been shown to range from 2.81 (95% CI: 0.38, 20.86) to 5.11 (95% CI: 0.7, 37.50). 6 Because argatroban is cleared by hepatic metabolism, patients with hepatic dysfunction may require close monitoring and dose adjustments.
1,2 Argatroban increases the international normalized ratio (INR) to a greater extent than other DTIs, which complicates the transition to warfarin therapy. 2, 6 Desirudin is currently approved in the United States for prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery 16 and has been shown to significantly reduce the incidence of deep vein thrombosis in hip surgery patients treated for 8-12 days compared with unfractionated heparin [desirudin group, 7% (13 of 174 patients); heparin group, 23% (41 of 177 patients), P , 0.0001] and the LMWH enoxaparin [desirudin group, 18% (142 of 773 patients); enoxaparin group, 26% (196 of 768 patients), P = 0.001]. 17, 18 The safety profile of desirudin was comparable to that of heparin and enoxaparin in these 2 studies. 17, 18 Desirudin has also been evaluated in clinical studies conducted in the settings of acute coronary syndromes and percutaneous interventions. [19] [20] [21] [22] [23] [24] [25] [26] [27] In these studies, the efficacy and safety profile of desirudin were similar to that of unfractionated heparin for the prevention of thrombosis.
The pharmacologic properties of desirudin, including thrombin-binding affinity, differ substantially from those of argatroban. 1, 2, 28, 29 Argatroban is a small, univalent DTI with moderate binding affinity for thrombin's active site (k i = 10 28 M). [28] [29] [30] Desirudin is a bivalent DTI that binds with a very high affinity to thrombin molecules (inhibitory constant, k i = 10 213 M). 29, 31 Preclinical data and data from large-scale clinical trials in acute coronary syndromes and percutaneous interventions have shown that bivalent inhibitors are more efficacious than are univalent inhibitors in preventing recurrent arterial thromboembolic events. 11, 28 We hypothesized that due to these pharmacologic differences, low-dose desirudin (15 mg Q12h) would be as efficacious as argatroban in patients with suspected HIT, with less bleeding.
Published data on direct clinical comparisons of DTIs in patients with suspected HIT are limited. 6 The PREVENT-HIT study (NCT00787332) was an open-label, multicenter exploratory study designed to evaluate the clinical and economic utility of a twice-daily fixed-dose of desirudin administered subcutaneously (SC) to prevent thrombosis in patients with suspected HIT with or without thrombosis compared with a continuous infusion of activated partial thromboplastin time (aPTT)-adjusted argatroban. Outcomes applied to assess efficacy and safety of the study medications included new or worsening thrombosis, amputation, all-cause mortality, time to platelet recovery, and major bleeding monitored through 30 days posttreatment. Details of the study methodology have been previously reported 32 and are summarized below.
MATERIALS AND METHODS

Study population
Men and nonpregnant women aged 18 years or older, with or without thrombosis, were eligible for inclusion in the study if HIT was clinically suspected. Inclusion and exclusion criteria are shown in Table 1 . The study was conducted in accordance with Good Clinical Practice guidelines and the ethical principles established by the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board and/or Ethics Committee at each study site, and written informed consent was obtained from all study participants (or their legal representative) before study initiation.
Study design
Block randomization was used to assign participants to treatment in a 1:1 ratio to 1 of 2 study arms, group A or group B. Patients naive to DTI therapy were placed in group A, and patients already receiving IV argatroban at study entry were placed in group B. Within each group, patients were randomized to receive either desirudin SC every 12 hours or argatroban administered by continuous IV infusion titrated to a therapeutic aPTT (ie, titrated until aPTT was 1.5-3 times baseline or as per the institutional standard of care at each study site). Patients receiving desirudin who did not present with clinical evidence of thrombosis received 15 mg of desirudin SC every 12 hours; those with clinical evidence of thrombosis at study entry received 30 mg of desirudin SC every 12 hours. Argatroban was administered in accordance with institutional policies at each study location or in accordance with approved prescribing information. 13 Patients were transitioned to warfarin therapy at the discretion of the investigator when their platelet counts had substantially recovered to .100,000 to 150,000 mm 3 .
Efficacy and safety assessments
The primary efficacy measure included the occurrence of one or more of the following events up to 30 days after discontinuation of study medication: new-onset or worsening thrombosis requiring discontinuation of study medication; amputation; or death from any cause. Secondary outcome measures included time to full recovery of platelets (defined as platelets $150,000 mm 3 ) and bleeding (major and minor). Drug acquisition costs, duration of therapy, drug management burden (including number of interventions required for dose adjustment and monitoring), and time to hospital discharge were also assessed.
Patients were closely monitored by study investigators via direct patient examinations for the duration of treatment, with complete blood counts and serum chemistries collected daily, hemoglobin and hematocrit levels collected as indicated, and platelet count measured at hospital discharge. Patients randomized to desirudin had peak and trough aPTT measurements collected around each daytime dose. Efficacy outcomes and safety parameters were monitored throughout the study and for 30 days after discontinuation of study medication.
Data analyses
Due to the exploratory nature of this study, no formal sample size calculations were conducted. Descriptive statistics were used to describe the data collected, including means, SDs, medians, interquartile ranges, minimum and maximum values for continuous variables and frequencies, and percentages for categorical variables. Intent-to-treat analyses included all enrolled patients who received at least 1 dose of study drug.
RESULTS
Patient demographics and characteristics
Study enrollment began in November 2008; the study was designed to enroll approximately 120 patients. However, the study was ended in December 2009 due to slow enrollment, after a total of 16 patients had enrolled. Eight patients were randomized to receive desirudin: 4 were assigned to study group A and 4 to group B. Eight patients were randomized to argatroban: 4 were assigned to group A and 4 to group B. Fifteen patients completed the study; 1 patient in group B receiving desirudin withdrew consent on day 5 of treatment. All 16 patients were included in efficacy and safety analyses.
Baseline demographics and patient characteristics at study entry are summarized in Table 2 . On average, patients randomized to treatment with desirudin were older (mean age, 69 years), and had a lower body weight (mean, 81 kg) compared with patients treated with argatroban (mean age, 62 years; mean body weight, 100 kg). Assays for HIT performed at participating institutions (heparin-induced platelet activation assay or heparin platelet factor-4 enzymelinked immunosorbent assay for the presence of IgG/A/M antibodies) were positive at baseline in 11 patients (70%), with a similar frequency between treatment groups. The mean baseline platelet count at study entry was lower in patients randomized to desirudin treatment compared with argatroban. Mean (interquartile range) platelet count at baseline was 84,000 mm 3 (63,000; 106,000) for group A patients receiving desirudin; 106,000 mm 3 (74,000; 125,000) for group A patients receiving argatroban; 91,000 mm 3 (20,000; 139,000) for group B patients receiving desirudin; and 137,000 mm 3 (37,000; 267,000) for group B patients receiving argatroban.
Each patient in the study had at least 6 active medical conditions at baseline (mean 13.9; range 6-32). The most common were hypertension, dyslipidemia, recent cardiac or vascular surgery, coronary artery disease, diabetes mellitus, congestive heart failure, and atrial fibrillation (Table 3) .
Thrombosis, bleeding-related events, and platelet count recovery Thrombosis and bleeding-related events that occurred during treatment with study medications are summarized in Table 4 . There were no deaths or amputations in either group. One patient randomized to argatroban had a worsening thrombosis, but study drug was not discontinued. No patient randomized to desirudin had a new thrombosis. Two patients receiving argatroban experienced major bleeding events during therapy: 1 patient experienced a decrease in hemoglobin from the judgment of the investigator, would place a patient at undue risk by being enrolled in the study or cause an inability to comply with the study 10.5 to 8.1 g/dL of blood, and 1 patient experienced 2 incidents of major gastrointestinal bleeding. These major bleeding events resolved without sequelae. One patient in each group experienced minor bleeding during treatment with study drug; 1 patient randomized to desirudin had heme-positive stool samples, and 1 patient randomized to argatroban after a below-theknee amputation experienced a minor bleed, described as a hematoma at the amputation site. There were no occurrences of new or worsening thromboses, amputations, or deaths during the 30-day follow-up period. Two incidents of major bleeding occurred during posttreatment follow-up: 1 patient randomized to argatroban experienced esophageal bleeding 6 days after study drug discontinuation, and 1 patient randomized to desirudin experienced a sublingual hematoma 2 weeks after study drug discontinuation due to an elevated INR on warfarin therapy.
There appeared to be no differences in the time to platelet count recovery or in the rate of platelet count recovery between the 2 groups (Fig. 1) . 
Economic measurements
The mean initial dose of argatroban was 1.6 mg/kg/min; 7 of 8 patients randomized to desirudin received 15 mg twice daily for the duration of treatment. The frequency and timing of dose changes for each patient randomized to argatroban are illustrated in Figure 2 . Peak and trough aPTT results for each patient receiving desirudin are illustrated in Figure 3 . Argatroban required dose adjustments 3.8 times per patient on average whereas the dose of desirudin was changed only once in 1 patient during the entire study (an increase from 15 mg every 12 hours to 30 mg every 12 hours due to low aPTT response on the 15-mg dose).
Median duration of treatment, length of hospital stay, and duration of warfarin overlap with study drug are summarized in Table 5 for the entire cohort and for patients with serologically confirmed HIT. Patients randomized to desirudin were on drug therapy for fewer days compared with patients randomized to argatroban (5 vs 7.5 days), despite having a lower baseline platelet count at randomization. Patients with serologically confirmed HIT (n = 11) were on drug therapy longer than the overall cohort (Table 5 ), but those randomized to desirudin had shorter durations of therapy (median, 7 days) compared with those randomized to argatroban (median, 11 days).
Time to initiate warfarin therapy did not differ between the groups, but patients randomized to desirudin (n = 5) had a mean of 5.0 INR tests performed compared with a mean of 8.7 tests among patients randomized to argatroban (n = 7).
Study medication costs were calculated using wholesale acquisition costs (January 2010 Red Book 33 ) of $150 per 15.75-mg vial of desirudin and $1100 per vial of argatroban. The mean cost of study medication per treatment day was $337.50 for desirudin and $1100 for argatroban. The median total cost of study medication per course of treatment was $1688 for desirudin and $8250 for argatroban. In addition to this potential cost benefit, median length of stay postrandomization was also shorter in patients who were randomized to desirudin (8 vs 14.5 days).
Tolerability
A total of 11 AEs were reported by 7 patients receiving desirudin, and 24 AEs were reported by 8 patients receiving argatroban. The majority of AEs across 
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American Journal of Therapeutics (2011) 18 (1) treatments (91%) were considered mild or moderate in intensity. The most frequently occurring AEs were tachycardia (1 patient receiving desirudin, 2 patients receiving argatroban), hypokalemia (3 patients receiving argatroban), skin rash (1 patient receiving desirudin, 1 patient receiving argatroban), leukocytosis (2 patients receiving argatroban), and atrial fibrillation (1 patient receiving desirudin, 1 patient receiving argatroban). Three serious AEs were reported. One patient receiving argatroban experienced an esophageal hematoma 6 days after argatroban was discontinued. This event was considered possibly related to study medication. One patient receiving argatroban experienced skin necrosis that required surgical revision of the amputation site. This event occurred 7 days after argatroban was discontinued and was not considered related to study medication. One patient receiving desirudin experienced a sublingual hematoma 16 days after desirudin was discontinued that was not considered related to study medication. All 3 serious AEs resolved. No deaths or discontinuations due to AEs occurred during the study.
DISCUSSION
To our knowledge, this is the first published report of results from a prospective, randomized study comparing 2 DTIs in the clinical setting of HIT. While interpretation of the results is inherently limited by the exploratory nature of the study, the open-label design, and the small patient population (N = 16), the data compiled from this small group of patients are informative and will be useful in the design of future studies.
The study population had complex medical histories with multiple comorbidities at entry (a mean of 14 comorbidities per patient), and the majority (14 of 16; 88%) had a recent history of cardiac or vascular surgery. Patients exposed to heparins postsurgery are known to be at the highest risk for HIT. 6 There were no occurrences of events included in the primary efficacy measure during the study. One patient randomized to argatroban had worsening thrombosis, documented by ultrasound and accompanied by symptoms. Because this event did not result in discontinuation of study drug, it did not meet the criteria defined by the primary efficacy measure for the study. Three incidents of major bleeding were reported in the argatroban group, and 2 incidents of minor bleeding also occurred, 1 in each group. At baseline, patients in the desirudin group appeared to have more severe thrombocytopenia than those in the argatroban group; the mean baseline platelet count of patients in the argatroban group was about 30,000 mm 3 higher than the mean platelet count in the desirudin group. Despite the difference in baseline platelet counts, time to platelet count recovery appeared to be similar in both treatment groups.
The duration of treatment was 2.5-4 days longer and length of hospital stay was 6-8 days longer for patients randomized to treatment with argatroban compared with patients randomized to desirudin treatment. Patients with serologically confirmed HIT receiving argatroban required a median of 2 days more of DTIwarfarin overlap than did patients receiving desirudin. Daily medication costs for argatroban were about 3 times greater than daily costs for desirudin.
Heparin is widely used in the United States. 34 Although the actual overall incidence of HIT is unknown, estimates range from about 24,000 35 to 600,000 new cases per year in the United States. 36 This study showed a median savings of $6562 in drug costs per course of treatment with desirudin compared with argatroban, or about 20% of the cost for a course of treatment with argatroban. Extrapolating this cost differential to the reported annual sales of argatroban of $137 million, this translates into an annual savings to the health care system of nearly $110 million in drug costs alone.
This study is obviously limited by the small sample size and open-label design. The study was designed as an exploratory pilot and planned to enroll 120 patients. However, enrollment was slow and the study was terminated early due to low enrollment. Common reasons for not including patients in the study included patient or family refusal of consent, severe or changing renal function, or severe concomitant illnesses.
Because of the low number of patients enrolled, conclusions cannot be drawn from the low rate of thrombosis or the high percentage of patients with serologically confirmed HIT observed in the study. The low rate of thrombosis may be due to chance, effectiveness of the treatments, or a lower-than-expected risk of thrombosis. Despite the high percentage of serologically confirmed HIT, it is possible that the underlying risk of thrombosis in this patient population is lower than the risk in historical trials of patients with HIT. Antibody tests commonly used in clinical practice have a high sensitivity for HIT, but a relatively modest specificity. 6, 7 Availability of ''gold standard'' plateletactivating tests, such as the serotonin release assay, is severely limited, as results are typically not immediately available and may take up to 1 week or longer. Because the consequences of HIT are dire and immediate anticoagulation is necessary to prevent amputation, thrombosis, or death, current guidelines recommend removing all sources of heparin and starting an alternative anticoagulant whenever there is a suspicion of HIT and before laboratory test results are available. 6, 7 Desirudin seems well suited for this clinical problem as it is from the same pharmacologic class as argatroban and costs less, with an improved safety profile demonstrated in large-scale studies of patients undergoing hip replacement surgery.
Desirudin appears to be a feasible and cost-effective alternative to argatroban in the setting of suspected and immunologically confirmed HIT, and further study is warranted in this patient population. Concomitant therapy with warfarin was easily accomplished during treatment with SC administered desirudin, permitting transition to warfarin monotherapy with fewer INR tests than argatroban.
